Abstracts tagged "Cardiovascular disease"

Abstract Number: 1475 • 2016 ACR/ARHP Annual Meeting
Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Non-Selective Nsaids in Taiwanese Rheumatoid Arthritis Patients
Tzu-Chieh Lin¹, Daniel H. Solomon², Sara K. Tedeschi¹, Kazuki Yoshida³ and Yea-Huei Kao Yang⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, Boston, MA, ³Department of Epidemiology, Harvard School of Public Health, Boston, MA, ⁴College of Medicine, National Cheng Kung University, Institute of Clinical Pharmacy and Pharmaceutical Science, Taian, Taiwan
Background/Purpose: Topical NSAIDs (tNSAIDs) have less systemic absorption than oral NSAIDs (oNSAIDs). Thus, tNSAIDs may be associated with a reduced cardiovascular disease (CVD) risk compared…
Abstract Number: 1714 • 2016 ACR/ARHP Annual Meeting
Risk of 10-Year Cardiovascular Disease Assessed By Framingham Risk Score Is Similar in Patients with Psoriatic Arthritis and Psoriasis As Assessed By Atherosclerotic Cardiovascular Disease and Framingham Risk Scores
Natsumi Ikumi¹, Agnes Szentpetery¹, Brian Kirby² and Oliver FitzGerald¹, ¹St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ²St. Vincent's University Hospital, Department of Dermatology, Dublin, Ireland
Background/Purpose: Patients with psoriatic arthritis (PsA) and psoriasis (PsO) are at increased risk of cardiovascular diseases (CVD) and the risk is higher in patients with…
Abstract Number: 2293 • 2016 ACR/ARHP Annual Meeting
Cardiometabolic Risk and Subclinical Urate Deposits in Patients with Symptomatic Hyperuricemia and Metabolic Syndrome
Seoyoung C. Kim¹, Rajesh Garg², Stacy Smith³, Alyssa Wohlfahrt⁴, Anarosa Campos⁵, Kathleen Vanni⁴, Lauren K Lee⁶, Penny Wang⁶, Zhi Yu⁷, Marcelo Di Carli⁸ and Daniel H. Solomon⁹, ¹Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ²Endocrinology, Brigham & Women's Hospital, Boston, MA, ³Radiology/Division of Musculoskeletal Imaging & Intervention, Brigham & Women's Hospital/ Harvard Medical School, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ⁸Div. of Nuclear Medicine, Brigham and Women's Hospital, Boston, MA, ⁹Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Elevated serum uric acid (sUA) levels, with and without gout, are associated with systemic inflammation, coronary artery disease (CAD), chronic kidney disease, and diabetes.…
Abstract Number: 128 • 2016 ACR/ARHP Annual Meeting
Call to Action: Cardiovascular Comorbidities in Medicare Rheumatology Beneficiaries
Gurjit S. Kaeley¹ and Sunita Dodani², ¹University of Florida, Ponte Vedra Beach, FL, ²Cardiology and Epidemiology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL
Background/Purpose: Cardiovascular (CV) manifestations of Rheumatological inflammatory diseases have become increasingly recognized, and, in some patients, might even constitute the initial presentation of a Rheumatological…
Abstract Number: 888 • 2016 ACR/ARHP Annual Meeting
Prevalence of Takayasu Arteritis in Young Women Presenting with Acute Ischemic Heart Disease
Giulio Cavalli, Alessandro Tomelleri, Elena Baldissera and Lorenzo Dagna, Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy
Background/Purpose: Ischemic heart disease (IHD) is classically considered a disease of older men. However, 10% of myocardial infarctions occur in patients aged <45; also, in…
Abstract Number: 1477 • 2016 ACR/ARHP Annual Meeting
Exploring the Inadequate Cardiovascular Disease Prevention in Inflammatory Joint Diseases: Results from a Nationwide Norwegian Project
Eirik Ikdahl¹, Silvia Rollefstad², Grunde Wibetoe³, Anne Salberg⁴, Dag Magnar Soldal⁵, Inge C Olsen⁶, Tore K Kvien⁷, Anne Grete Semb¹ and Glenn Haugeberg⁸, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Martina Hansens Hospital, Bærum, Norway
Background/Purpose: Antihypertensives (antiHT) and lipid lowering therapies (LLT) prevent cardiovascular disease (CVD) effectively. It has been reported that patients with rheumatoid arthritis (RA) receive suboptimal…
Abstract Number: 1727 • 2016 ACR/ARHP Annual Meeting
Association Between Biologic Therapies and Major Adverse Cardiac Events or Cardiac Heart Failure in Psoriatic Arthritis or Psoriasis: A Meta-Analysis
Benedicte Champs, Rheumatology, Medecine Toulouse Purpan Hospital, Lescure d'albigeois, France
Association between biologic therapies and major adverse cardiac events or cardiac heart failure in psoriatic arthritis or psoriasis: a meta-analysis. 1Champs B, 1Degboe Y, 1Ruyssen-Witrand…
Abstract Number: 2359 • 2016 ACR/ARHP Annual Meeting
Dose-Related Risks of Cardiovascular, Gastrointestinal, and Renal Adverse Events Associated with Meloxicam Among Patients with Osteoarthritis: An Observational Study Using US Claims Data
Elaine Hoffman¹, Deirdre M. Mladsi¹, Byron Cryer², William Hopkins³, D. Craig Brater⁴, Rohan Parikh¹, Ravi Goyal¹, Jordi Castellsague⁵, Dana Stafkey-Mailey⁶ and Clarence Young⁷, ¹Health Economics, RTI Health Solutions, Research Triangle Park, NC, ²University of Texas Southwestern Medical School, Dallas, TX, ³Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT, ⁴Indiana University School of Medicine, Bloomington, IN, ⁵Epidemiology, RTI Health Solutions, Barcelona, Spain, ⁶Xcenda, AmerisourceBergen, Palm Harbor, FL, ⁷Iroko Pharmaceuticals, LLC, Philadelphia, PA
Background/Purpose: Safety studies have shown that risks associated with non-steroidal anti-inflammatory drugs (NSAIDs) are related to dose; however, there is little evidence regarding this dose-toxicity…
Abstract Number: 232 • 2016 ACR/ARHP Annual Meeting
Impact of Gout Flare Prophylaxis and Urate-Lowering Therapy on Endothelial Function, Smooth Muscle Responsiveness and Markers of Inflammation: Results of a Prospective Observational Pilot Study
Talia Igel^1,2, Aaron Garza Romero², Virginia Pike³, Stuart Katz⁴, Binita Shah⁵, Irina Dektiarev⁴, Svetlana Krasnokutsky Samuels⁶ and Michael H. Pillinger⁷, ¹Monash University School of Medicine, Melbourne, Australia, ²Medicine/Rheumatology, NYU School of Medicine, New York, NY, ³Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ⁴Medicine/Cardiology, NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, Division of Cardiology, New York, NY, ⁶Svetlana Krasnokutsky, NYU Hospital for Joint Diseases, New York, NY, ⁷NYU School of Medicine, New York, NY
Background/Purpose: To date, most studies of gout and cardiovascular disease have been cross-sectional or retrospective, and have addressed the outcome of acute coronary syndromes. Less…
Abstract Number: 896 • 2016 ACR/ARHP Annual Meeting
Risk for Cardiovascular Disease in Giant Cell Arteritis and Polymyalgia Rheumatica
Florencia Beatriz Mollerach¹, Emmanuel Bertiller¹, Maria de los Angeles Gallardo², Maximiliano José Martinez¹, Marina Scolnik³, Javier Rosa¹, Luis J. Catoggio⁴ and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Hospital Italiano de Buenos Aires, CABA, Argentina, ³Rheumatology Section, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina
Background/Purpose: chronic inflammatory diseases are at a substantially increased risk of cardiovascular events (CVE). Scarce data is available in patients with Giant cell arteritis (GCA)…
Abstract Number: 1479 • 2016 ACR/ARHP Annual Meeting
Cardiovascular Diseases and Mortality Are Independently Influenced By Carotid Plaque Presence in Rheumatoid Arthritis: The 5-Year Prospective Study
Jung Su Eun¹, Eun Song Lee², Jong Wan Kang¹, Na Ri Kim¹, Ji Hun Kim¹, Jin Young Kang¹, Eon Jeong Nam³ and Young Mo Kang¹, ¹Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, The Republic of, ²Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher risk of cardiovascular disease (CVD) and premature mortality, compared to the general population. Inflammatory burden and conventional…
Abstract Number: 1782 • 2016 ACR/ARHP Annual Meeting
Subclinical Myocarditis in Systemic Lupus Erythematosus Patients without Cardiovascular Disease
Laura Geraldino-Pardilla¹, Thania Perez², Sabahat Bokhari³, Joan Bathon⁴ and Anca D. Askanase⁵, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Columbia University College of Physicians & Surgeons, New York, NY, ³Cardiology, Columbia University College of Physicians & Surgeons, NY, NY, ⁴Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁵Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose : Cardiovascular disease (CVD) remains a leading cause of death in SLE. Lupus patients have a 2-3 fold increased risk to develop heart failure…
Abstract Number: 2504 • 2016 ACR/ARHP Annual Meeting
Impaired Vasodilator Function in Rheumatoid Arthritis Patients Who Flared Due to Stopping Adalimumab or Etanercept
Gerard A Rongen¹, Iris van Ingen² and Tim L Jansen^3,4, ¹Internal Medicine/Pharmacology and Toxicology, Radboud UMC, Nijmegen, Netherlands, ²Rheumatology, RadboudUMC, Nijmegen, Netherlands, ³Rheumatology, VieCuri Medical Centre, Venlo, Netherlands, ⁴Scientific IQ HealthCare, Radboud UMC, Nijmegen, Netherlands
Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) is associated with an increased cardiovascular risk, possibly due to disrupted vascular vasodilation. Within 12 weeks adalimumab and…
Abstract Number: 233 • 2016 ACR/ARHP Annual Meeting
New Cardiovascular Risk Factors Screening in Patients with Gout
Juan Carlos Ordoñez¹, Mariano Andres¹, Francisca Sivera², Loreto Carmona³, Paloma Vela^4,5, Eliseo Pascual^4,5 and Jose Antonio Bernal⁴, ¹RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain, ²RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO DE ELDA, Elda, Spain, ³Instituto de Salud Musculo Esqueletica, Madrid, Spain, ⁴RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO ALICANTE, Alicante, Spain, ⁵Medicina, Universidad Miguel Hernandez, Elche, Spain
Background/Purpose: Gout is a disease triggered by the crystallization of uric acid in the joints secondary to persistent hyperuricemia, that leads to chronic inflammation. Patients…
Abstract Number: 905 • 2016 ACR/ARHP Annual Meeting
Platelet Activation, As Measured By Plasma Soluble Glycoprotein VI, Is Not Associated with Disease Activity or Ischaemic Events in Giant Cell Arteritis
Richard Conway¹, Anne Madigan², Laura Helbert³, Niamh Redmond⁴, Eimear Dunne⁵, Eamonn S. Molloy⁶, Dermot Kenny⁵ and Geraldine M. McCarthy⁷, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ³Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁴UCD Clinical Research Centre, Dublin, Ireland, ⁵Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ⁶Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin, Ireland, ⁷Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Patients with Giant Cell Arteritis (GCA) have an increased risk of devastating cranial ischaemic complications including vision loss and stroke. The BSR guidelines recommend…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].